Phase I Study of Pembrolizumab in Combination with Ibrutinib for the Treatment of Unresectable or Metastatic Melanoma
Frontiers in immunology（2025）
Key words
melanoma,ibrutinib,pembrolizumab,Th2 (type-2) immune responses,Th1 immune responses,immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined